1.56
-0.12(-7.14%)
Currency In USD
| Previous Close | 1.68 |
| Open | 1.67 |
| Day High | 1.72 |
| Day Low | 1.55 |
| 52-Week High | 1.85 |
| 52-Week Low | 0.77 |
| Volume | 1.82M |
| Average Volume | 1.39M |
| Market Cap | 147.5M |
| PE | -3.12 |
| EPS | -0.5 |
| Moving Average 50 Days | 1.25 |
| Moving Average 200 Days | 1.2 |
| Change | -0.12 |
If you invested $1000 in SELLAS Life Sciences Group, Inc. (SLS) 10 years ago, it would be worth $0.04 as of May 10, 2025 at a share price of $1.56. Whereas If you bought $1000 worth of SELLAS Life Sciences Group, Inc. (SLS) shares 5 years ago, it would be worth $537.93 as of May 10, 2025 at a share price of $1.56.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference
GlobeNewswire Inc.
Apr 28, 2025 12:45 PM GMT
New Data Suggest SLS009 (tambiciclib) May Overcome Resistance to Azacitidine-Venetoclax Regimen and Trigger Apoptosis of TP53 Mutated AML CellsNEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or
SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire Inc.
Apr 23, 2025 2:23 PM GMT
- ASCO Presentation to Highlight Preclinical Efficacy of SLS009 (tambiciclib) in ASXL1 Mutated Colorectal Cancer -NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage
SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML
GlobeNewswire Inc.
Apr 08, 2025 12:45 PM GMT
- 8.9 Months Median Overall Survival (mOS) in Patients with AML-Myelodysplasia-Related Changes (AML-MRC) and 8.8 mOS in All Relapsed or Refractory to Venetoclax-Based Regimens Patients; Surpassing Historical Benchmark of 2.5 Months - - Overall Respon